As of Jul 31, 2026, LGND's PEG ratio of 0.17 reflects its valuation relative to its growth. This value reflects a P/E ratio of 36.4 measured against EPS growth of 209.7%.
Ligand Pharmaceuticals Inc - Class B's nine years historical PEG ratio has a mean of 0.18. Compared to historical data, LGND's 0.17 PEG ratio represents a decrease of 6%. LGND reached its maximum PEG ratio of 1.5 during the Sep 2017 quarter over the past nine years. The Mar 2019 quarter had the bottom reading at 0, indicating the most optimal growth-adjusted valuation.
| Year | PEG ratio | PE ratio | Growth YoY |
|---|---|---|---|
| 2025 | 0.01 | 29.36 | 3,027.3% |
| 2024 | N/A | N/A | -107.3% |
| 2023 | 0.09 | 23.65 | 252.5% |
| 2022 | N/A | N/A | -157.6% |
| 2021 | 0.02 | 44.9 | 2,011.1% |
| 2020 | N/A | N/A | -100.5% |
| 2019 | 0.01 | 3.15 | 389.4% |
| 2018 | 0.02 | 20.04 | 1,028.3% |
| 2017 | 0.27 | 228.22 | 850% |
| 2016 | N/A | N/A | -100.7% |
| 2015 | 0.01 | 9.34 | 1,867.8% |
| 2014 | 16.7 | 90.19 | 5.4% |
| 2013 | 0.05 | 93.93 | 1,966.7% |
| 2012 | N/A | N/A | -106.1% |
| 2011 | 0.13 | 24.22 | 192.5% |
| Year | PEG ratio | PE ratio | Growth YoY |
|---|---|---|---|
| Mar 2026 | 0.12 | 25.27 | 209.7% |
| Dec 2025 | 0.01 | 29.36 | 3,027.3% |
| Sep 2025 | N/A | 76.68 | -12.5% |
| Jun 2025 | N/A | N/A | -266.8% |
| Mar 2025 | N/A | N/A | -232.1% |
| Dec 2024 | N/A | N/A | -107.3% |
| Sep 2024 | 0.22 | 37.91 | 175% |
| Jun 2024 | 0.62 | 34.53 | 55.4% |
| Mar 2024 | 0.05 | 13.41 | 292.1% |
| Dec 2023 | 0.09 | 23.65 | 252.5% |
| Sep 2023 | 0.36 | 62.42 | 175.6% |
| Jun 2023 | 0.11 | 45.92 | 434% |
| Mar 2023 | N/A | 52.92 | -2.1% |
| Dec 2022 | N/A | N/A | -157.6% |
| Sep 2022 | N/A | N/A | -130.8% |
LGND's PEG ratio today sits above its 5-year average, yet it is lower than the 3 and 10-year averages.
With a PEG of 0.17, LGND stands below the Healthcare sector and the industry average. Looking at its Healthcare sector average of 0.56, Ligand Pharmaceuticals Inc - Class B's PEG is 70% lower.
LGND has a PEG ratio below that of peer stocks LLY and AMGN.
| Stock name | PEG ratio | Market cap |
|---|---|---|
| BMY Bristol-Myers Squibb Company | 0.17 | $132.74B |
| LGND Ligand Pharmaceuticals Inc - Class B | 0.17 | $5.81B |
| LLY Lilly(Eli) & Company | 0.31 | $1.05T |
| AMGN AMGEN Inc | 0.84 | $204.68B |
| MRK Merck & Co Inc | N/A | $315.05B |
| PFE Pfizer Inc | N/A | $142.12B |
| JNJ Johnson & Johnson | N/A | $610.56B |
| BAX Baxter International Inc | N/A | $14.43B |
LGND's Jul 31, 2026 PEG ratio comes in at 0.17.
LGND has a 3-year average PEG ratio of 0.21.
LGND has a 5-year average PEG ratio of 0.16.
In the last nine years, LGND's peak PEG ratio of 1.5 was recorded in the Sep 2017 quarter.
Currently, LGND's PEG ratio is 6% lower than its 9-year historical average.
The 0.17 PEG ratio for LGND reflects strong earnings growth outpacing the current valuation.
The PEG ratio comes from taking PE and dividing by the rate at which earnings are growing (YoY TTM). As of Jul 31, 2026, Ligand Pharmaceuticals Inc - Class B has a P/E ratio of 36.4. Earnings grew at 209.7% over the TTM period ending Mar 2026. Applying the formula, this gives a price to earnings growth ratio of 0.17. PEG RATIO(0.17) = PE RATIO(36.4) / EPS GROWTH(209.7%)
All PEG ratio stats are based on quarterly TTM periods, unless otherwise specified.